Healthcare industry renews pressure on FDA to address DEHP concerns
This article was originally published in Clinica
Executive Summary
At the time of going to press, the US Food and Drug Administration had not responded to the request submitted by a consortium of healthcare providers and a public interest group over a month ago, asking for a new labelling regulation that specifically targets medical devices that may leach potentially dangerous chemicals into the bloodstream.